If you ask a community psychiatrist anywhere in the world to name a medication they have prescribed thousands of times, haloperidol decanoate will be on the short list. Introduced in the 1980s, it became one of the most widely used long-acting injectable antipsychotics — partly because it works, partly because it is cheap, and partly because it sits on the WHO Model List of Essential Medicines and is therefore broadly available. Like fluphenazine decanoate, it carries the side effect profile of a high-potency first-generation antipsychotic, and that profile is the conversation worth having before starting it.
Haloperidol decanoate is a long-acting injectable form of haloperidol given roughly once a month, with strong evidence for relapse prevention and a higher rate of movement-related side effects than second-generation LAIs.
What it is
Haloperidol decanoate (often referred to by the brand name Haldol Decanoate, though most prescriptions are now generic) is the decanoate ester of haloperidol dissolved in sesame oil. After deep intramuscular injection, the ester is slowly hydrolysed, releasing haloperidol over weeks. It is FDA-approved for the maintenance treatment of schizophrenia in patients who have been previously stabilised on oral haloperidol.
Calculating the dose
One of the practical features of haloperidol decanoate is that there is a widely used conversion guideline: the monthly depot dose is typically about 10 to 20 times the previous daily oral dose. So a patient stable on 5 mg of oral haloperidol per day might start on 50–100 mg of decanoate every four weeks. This is a starting point, not a fixed rule — adjustments are made based on response and tolerability.
Many prescribers begin with a smaller test dose to confirm tolerance, then build up over the first few injections. Some clinicians also continue oral haloperidol at a tapering dose for the first month or two while the depot levels build up. Specifics depend on prescriber preference, the inpatient or outpatient setting, and the patient's prior exposure.
Dosing schedule
Standard intervals are every four weeks, although three- or six-week intervals are sometimes used. The maximum recommended single dose is generally 100 mg per injection; if the calculated dose is larger, it is split between two injection sites or given a few days apart. Maintenance doses commonly fall in the 50–200 mg every four weeks range, again individualised to the patient.
What it's good at
- Preventing relapse — strong evidence in randomised trials and naturalistic cohorts
- Reducing positive symptoms — hallucinations and delusions
- Adherence — once-monthly dosing removes the daily decision to take a pill
- Cost — among the cheapest LAIs available globally
Side effects to expect
The defining feature of haloperidol decanoate is its rate of extrapyramidal symptoms (EPS). Compared with newer LAIs, the rate of acute dystonia, drug-induced parkinsonism, akathisia, and tardive dyskinesia is meaningfully higher. The 2009 CATIE-style comparisons and a number of network meta-analyses including Schneider-Thoma et al. (Lancet, 2022) consistently show this tradeoff.
- Acute dystonia — usually in the first days; treatable with anticholinergics like benztropine
- Parkinsonism — tremor, stiffness, slowed movement
- Akathisia — restlessness, urge to move; one of the most distressing side effects
- Tardive dyskinesia — long-term risk that increases with cumulative exposure
- Hyperprolactinemia — sexual side effects, breast tenderness
- Sedation — typically modest but variable
- Injection-site reactions — pain, induration, occasional sterile abscess
You develop high fever with muscle rigidity and altered consciousness (neuroleptic malignant syndrome — rare but life-threatening), severe muscle spasms in the neck, jaw, or eyes, or any persistent involuntary movements that are new.
QT and cardiac considerations
Haloperidol can prolong the QT interval on the ECG. The risk is greater at higher doses, with intravenous administration, and in combination with other QT-prolonging drugs or low potassium and magnesium. The FDA label includes a warning about sudden cardiac events. Baseline ECG and electrolyte checks are reasonable, especially in older patients or those with cardiac risk factors.
Monitoring schedule
- AIMS (Abnormal Involuntary Movement Scale) — at baseline and every 6 months
- EPS rating — at each injection visit, especially in the first 6 months
- Prolactin level — if symptoms suggest hyperprolactinemia
- Metabolic labs — fasting glucose, lipids, weight; less concerning than with olanzapine but still tracked
- ECG — when indicated by other risk factors
Where it sits today
In high-resource settings, second-generation LAIs (paliperidone, risperidone, aripiprazole) are generally preferred when affordability is not the limiting factor, primarily because of the lower EPS burden. Haloperidol decanoate remains an important and effective option for patients who have done well on it historically, who cannot afford newer agents, or who prefer it after an informed conversation. The WHO Essential Medicines List and many national formularies continue to include it for this reason.
Useful questions for your prescriber
- Why this medication rather than a second-generation LAI?
- What dose are we starting at, and how was it calculated from my oral dose?
- Will I continue oral haloperidol during the transition?
- What is our plan if I develop EPS or akathisia?
- How will we monitor for tardive dyskinesia long-term?
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed sources. Always consult your prescribing clinician before starting, stopping, or changing any medication.